Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the application value of circulating tumor DNA(ctDNA) with efficacy evaluation and prognostic assessment in patients with unresectable SCLC, who were receiving radiotherapy and chemotherapy treatment.


Clinical Trial Description

1. According to each point in time of ctDNA, to analyze the dynamic changes of tumor burden and clonal subtypes which to evaluate the application value of ctDNA in curative efficacy evaluation. 2. Compare the two time points before and after radiotherapy and chemotherapy treatment of the cell free DNA (cfDNA) concentration and tumor burden, analysis the correlation between the changes and prognosis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05066945
Study type Observational
Source Xiangya Hospital of Central South University
Contact Deng
Phone 13574888840
Email [email protected]
Status Not yet recruiting
Phase
Start date January 1, 2022
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02179528 - Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC) Phase 2
Recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Lung Cancer or Melanoma N/A
Not yet recruiting NCT05027867 - KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer Phase 2
Completed NCT03325816 - Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT00003496 - Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer Phase 2
Completed NCT03059667 - Immunotherapy as Second-line in Patient With Small Cell Lung Cancer Phase 2
Recruiting NCT03923270 - Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer Phase 1
Recruiting NCT04462276 - Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease Phase 2
Not yet recruiting NCT04967625 - A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC Phase 2
Recruiting NCT04659785 - A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer(FA-ES-SCLC) Phase 1/Phase 2
Not yet recruiting NCT03755115 - SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer Phase 2
Recruiting NCT03994744 - Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC Phase 2
Active, not recruiting NCT03253068 - Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer Phase 2